Prevention of Hepatitis C Virus (HCV) and HIV-1 Co-Infections
A collaborative project financed by the EC Framework Programme 7
Our current technology is based on simian adenovirus (ChAd) prime/ modified vaccinia virus Ankara (MVA) boost vaccine regimes that are both safe and highly immunogenic in healthy volunteers.
The project has three major goals:
1. Assess the safety and immunogenicity of adenovirus prime / MVA boost HCV vaccines in HIV-1+ people who are treated with combination antiretroviral therapy (cART)
2. Conduct phase I clinical studies using two distinct simian adenoviral vectors simultaneously
Hepatitis C Virus (HCV)
Human Immunodeficiency Virus type 1 (HIV-1)
Combination Anti-Retroviral Therapy (cART)
Simian Adenovirus (ChAd)
Modified Vaccinia virus Ankara (MVA)
MHC class II invariant chain (li)
This strategy aims to prime responses against both HCV and HIV-1 antigenic targets concurrently
Recent work by consortium members has shown that the immunogenicity of both adenoviral and MVA vectors is markedly improved when the encoded HCV immunogen is fused to mouse or human MHC class II invariant chain (Ii).
3. Evaluation of novel technology in humans